Standout Papers

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer... 2005 2026 2012 2019 2.6k
  1. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer (2012)
    Sunil Verma, David Miles et al. New England Journal of Medicine
  2. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer (2019)
    Talia Golan, Pascal Hammel et al. New England Journal of Medicine
  3. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study (2020)
    Ghassan K. Abou‐Alfa, Vaibhav Sahai et al. The Lancet Oncology
  4. HER2-targeted therapies — a role beyond breast cancer (2019)
    Do‐Youn Oh, Yung‐Jue Bang Nature Reviews Clinical Oncology
  5. Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib (2005)
    Sae‐Won Han, Tae‐You Kim et al. Journal of Clinical Oncology
  6. Biliary tract cancer (2021)
    Juan W. Valle, Robin Katie Kelley et al. The Lancet
  7. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma (2019)
    Eileen M. O’Reilly, Do‐Youn Oh et al. JAMA Oncology
  8. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (2018)
    Jin‐Young Jang, Youngmin Han et al. Annals of Surgery
  9. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial (2023)
    Funda Meric‐Bernstam, Vicky Makker et al. Journal of Clinical Oncology
  10. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies (2020)
    Sarina A. Piha‐Paul, Do‐Youn Oh et al. International Journal of Cancer
  11. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study (2022)
    Michele Maio, Paolo A. Ascierto et al. Annals of Oncology
  12. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. (2022)
    Do‐Youn Oh, Aiwu Ruth He et al. Journal of Clinical Oncology
  13. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024)
    Simron Singh, Daniel Halperin et al. The Lancet
  14. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial (2024)
    Howard A. Burris, Takuji Okusaka et al. The Lancet Oncology

Immediate Impact

4 by Nobel laureates 4 from Science/Nature 98 standout
Sub-graph 1 of 20

Citing Papers

Pancreatic cancer
2025 Standout
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
2024 Standout

Works of Do‐Youn Oh being referenced

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2019 Standout
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
2019 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Do‐Youn Oh 14383 6384 5149 567 20.0k
Jacek Jassem 11155 7771 3192 510 19.3k
Volker Heinemann 14164 6028 3797 654 19.8k
Jordan Berlin 15107 6177 3357 351 22.4k
Andrés Cervantes 17546 9130 8193 459 26.9k
Filippo de Braud 17473 8522 5482 749 26.0k
Herbert I. Hurwitz 17516 7651 3686 318 26.3k
Hyun Cheol Chung 14781 13659 6961 577 26.9k
Pierfranco Conté 16376 7447 3785 684 25.1k
Anthony T.�C. Chan 11344 5465 7002 453 26.8k
Ian Chau 12763 6982 5277 463 18.2k

All Works

Loading papers...

Rankless by CCL
2026